Microbiotica Closes £36M First Tranche of Series C for MB310
British Business Bank led Microbiotica's £36M/$48M Series C first close to advance MB310 into Phase 2. Valuation and a final round target remain undisclosed.
life-sciences — Venture Capital Articles & Research
Explore our latest articles on life-sciences — covering venture capital deals, fund activity, startup fundraising strategy, and investor research relevant to this topic.
Whether you're a founder building an investor target list, an analyst tracking deal flow, or an operator researching market trends, the articles below provide practical, up-to-date venture capital intelligence.
Why This Topic Matters in VC
- Deal flow signal: Funding activity and investor conviction in life-sciences
- Fundraising context: Which investors are active and what traction they expect
- Market timing: Sector momentum, valuation benchmarks, and competitive dynamics
Browse all life-sciences articles below, or use our investor list to research active investors by stage and sector.
Related Articles (2 articles)
-
-
Buffalo Startups and VC Firms in 2026: ACV Auctions, 43North, and Life Sciences Capital
Buffalo’s venture map in 2026 — ACV Auctions (NASDAQ: ACVA), Guidesly, PostProcess, Roswell/UB spinouts, plus 43North, Launch NY, and Rand Capital.